RECRUITING

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Talk to us

Conditions

Bladder CancerNMIBCCISTa/T1BCG UnresponsiveVesical instillation treatment

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting

Official Title

ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

Quick Facts

Study Start:2023-09-15
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06026332

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Prescribed and scheduled treatment with ADSTILADRIN per physician discretion or received the first instillation of ADSTILADRIN per physician discretion after 5 September 2023 but prior to site activation
  2. * Signed and dated ICF.
  3. * Age 18 years or older at day ICF is signed.
  1. * Currently enrolled in a clinical trial.
  2. * Participants who have previously been treated with ADSTILADRIN in the context of a clinical trial
  3. * Participant is pregnant or breastfeeding.

Contacts and Locations

Study Contact

Global Clinical Compliance
CONTACT
1-888-FERRING (1-888-337-7464)
MedqueriesUS@ferring.com
Global Clinical Compliance
CONTACT
+1 862-286-5200 (outside US)
DK0-Disclosure@ferring.com

Principal Investigator

Global Clinical Compliance
STUDY_DIRECTOR
Ferring Pharmaceuticals

Study Locations (Sites)

Ferring Investigational Site
Gilbert, Arizona, 85234
United States
Ferring Investigational Site
Little Rock, Arkansas, 72211
United States
Ferring Investigational Site
Fresno, California, 93720
United States
Ferring Investigational Site
Los Angeles, California, 90033
United States
Ferring Investigational Site
Gainesville, Florida, 32608
United States
Ferring Investigational Site
Atlanta, Georgia, 30328
United States
Ferring Investigational Site
Greenwood, Indiana, 46143
United States
Ferring Investigational Site
Jeffersonville, Indiana, 47130
United States
Ferring Investigational Site
Wichita, Kansas, 67226
United States
Ferring Investigational Site
Baltimore, Maryland, 21287
United States
Ferring Investigational Site
Rochester, Minnesota, 55905
United States
Ferring Investigational Site
Omaha, Nebraska, 68114
United States
Ferring Investigational Site
Bronx, New York, 10467
United States
Ferring Investigational Site
New York, New York, 10032
United States
Ferring Investigational Site
Syracuse, New York, 13210
United States
Ferring Investigational Site
Gahanna, Ohio, 43230
United States
Ferring Investigational Site
Myrtle Beach, South Carolina, 29572
United States
Ferring Investigational Site
Nashville, Tennessee, 37209
United States
Ferring Investigation Site
Dallas, Texas, 75390
United States
Ferring Investigational Site
Charlottesville, Virginia, 22908
United States
Ferring Investigational Site
Virginia Beach, Virginia, 23462
United States

Collaborators and Investigators

Sponsor: Ferring Pharmaceuticals

  • Global Clinical Compliance, STUDY_DIRECTOR, Ferring Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-15
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2023-09-15
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Bladder cancer
  • NMIBC
  • CIS
  • Ta/T1
  • BCG Unresponsive
  • Vesical instillation treatment

Additional Relevant MeSH Terms

  • Bladder Cancer